Applications

• Immune-mediated drug-induced liver injury (DILI)

• MASH and MAFLD inflammation and disease progression models

• Liver fibrosis models in co-culture with hepatic stellate cells

• Innate immune activation, phagocytosis and cytokine release assays

• 3D liver microtissue and multicellular co-culture systems

• Donor-mismatched and allogeneic immune-response studies using HLA-typed lines

Donor diversity and HLA typing

Every Cytochroma cell model is differentiated from an induced pluripotent stem cell library built deliberately for population-level variability rather than convenience. 8 of 18 of 18 iPSC donor lines fully HLA-typed at two-field resolution. 71 distinct HLA alleles across the panel. 1:1 female to male donor balance. European, Native American and African ancestry represented. Pairwise HLA mismatch scores of 7 to 10 out of 10 between almost every donor pair, across HLA-A, B, C, DRB1 and DQB1.

Typing covers the classical class I loci HLA-A, HLA-B and HLA-C and the class II loci DRB1, DRB3/4/5, DQA1, DQB1, DPA1 and DPB1 at two-field resolution. Full multi-field typing is available on request. Because almost every donor pair scores 7 to 10 out of 10 on pairwise allele-level mismatch, donor-mismatched co-culture, allogeneic response and HLA-restriction studies can be set up off the shelf.

Evidence and validation

Released against a defined specification

Every batch is released against a written specification covering purity, viable recovery, mycoplasma, sterility, morphology, adherence, a five-gene qPCR identity panel and CD68 immunofluorescence, and ships with a Certificate of Analysis.

Diversity built in

Kupffer cells are differentiated from the same ancestrally diverse, HLA-typed iPSC library as Cytochroma hepatocytes, so immune and parenchymal compartments can be genotype-matched or deliberately mismatched.

OASIS Consortium

Cytochroma is an Advanced Liver Partner in the OASIS Consortium (’Omics for Assessing Signatures for Integrated Safety), a pre-competitive hepatic-safety consortium convened in July 2023 by HESI Global and the Broad Institute of Harvard and MIT as a working group of HESI’s eSTAR committee. OASIS integrates transcriptomics, proteomics and high-content Cell Painting across human-relevant models, with an initial focus on liver safety, and spans more than 160 experts across 17 academic institutes, 7 government agencies, 17 industry organisations and 3 NGOs. Cytochroma contributes diverse-donor human liver models to the consortium’s hepatic-safety programme. See The OASIS Consortium: Integrating Multi-Omics Technologies to Transform Chemical Safety Assessment, Rouquié et al., Toxicological Sciences 2025, 208(2), 225 (DOI 10.1093/toxsci/kfaf128).